SCHEMBL259329

SCHEMBL259329

CC(=O)Oc1ccc(-c2nc3c(oc4ncccc43)c(=O)[nH]2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 11/20 0.42
TNKS2 Q9H2K2 10/20 0.42
PARP1 P09874 8/20 0.42
GUSB P08236 2/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
PIM1 P11309 3/20 0.38
CSNK2A2 P19784 3/20 0.38
CSNK2B P67870 3/20 0.38
PIM3 Q86V86 3/20 0.38
PIM2 Q9P1W9 3/20 0.38
TP53 P04637 1/20 0.38
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PARP2 Q9UGN5 2/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259059 0.89 ALDH1A1 (0.48) PARP1ALDH1A1LMNAMAPT
SCHEMBL259307 0.87 TNKS2 (0.56) TNKSTNKS2PARP1GUSBNPC1
SCHEMBL259264 0.82 PDE5A (0.54) GUSBPIM1CSNK2A2CSNK2BPIM3
SCHEMBL259214 0.82 TNKS (0.49) TNKSTNKS2PARP1GUSBNPC1
SCHEMBL13318878 0.79 PIM1 (0.40) TNKSTNKS2PARP1NPC1RAB9A
SCHEMBL259304 0.78 PIK3CA (0.54) TNKSTNKS2PARP1PIM1CSNK2A2
SCHEMBL259355 0.78 TNKS (0.56) TNKSTNKS2PARP1GUSBNPC1
SCHEMBL259271 0.74 PIM1 (0.44) TNKSTNKS2PIM1CSNK2A2CSNK2B
SCHEMBL13318641 0.73 PIM3 (0.41) TNKSTNKS2PARP1NPC1RAB9A
SCHEMBL259377 0.73 CSNK2A2 (0.61) TNKSTNKS2GUSBPIM1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A TNKS 578/4885TNKS2 487/4885PARP1 1165/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A TNKS 578/4885TNKS2 487/4885PARP1 1165/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A TNKS 578/4885TNKS2 487/4885PARP1 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.